These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 38007397)
1. Patient Priorities Concerning Treatment Decisions for Advanced Neuroendocrine Tumors Identified by Discrete Choice Experiments. Anaka M; Chan D; Pattison S; Thawer A; Franco B; Moody L; Jackson C; Segelov E; Singh S Oncologist; 2024 Mar; 29(3):227-234. PubMed ID: 38007397 [TBL] [Abstract][Full Text] [Related]
2. Comparing Discrete Choice Experiment with Swing Weighting to Estimate Attribute Relative Importance: A Case Study in Lung Cancer Patient Preferences. Veldwijk J; Smith IP; Oliveri S; Petrocchi S; Smith MY; Lanzoni L; Janssens R; Huys I; de Wit GA; Groothuis-Oudshoorn CGM Med Decis Making; 2024 Feb; 44(2):203-216. PubMed ID: 38178591 [TBL] [Abstract][Full Text] [Related]
3. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481 [TBL] [Abstract][Full Text] [Related]
4. Patient Preferences Concerning Alternative Treatments for Neuroendocrine Tumors: Results of the "PIANO-Study". Mühlbacher AC; Juhnke C Int J Technol Assess Health Care; 2019 Jan; 35(3):243-251. PubMed ID: 31044688 [TBL] [Abstract][Full Text] [Related]
5. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002 [TBL] [Abstract][Full Text] [Related]
6. [Patients' Priorities in the Treatment of Neuroendocrine Tumours: An Analytical Hierarchy Process]. Mühlbacher AC; Juhnke C; Kaczynski A Gesundheitswesen; 2016 Oct; 78(10):651-657. PubMed ID: 26110243 [No Abstract] [Full Text] [Related]
7. Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma. Mühlbacher AC; Nübling M Eur J Health Econ; 2011 Jun; 12(3):193-203. PubMed ID: 20107856 [TBL] [Abstract][Full Text] [Related]
9. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166 [TBL] [Abstract][Full Text] [Related]
10. Does the inclusion of a cost attribute result in different preferences for the surgical treatment of primary basal cell carcinoma?: a comparison of two discrete-choice experiments. Essers BA; van Helvoort-Postulart D; Prins MH; Neumann M; Dirksen CD Pharmacoeconomics; 2010; 28(6):507-20. PubMed ID: 20387912 [TBL] [Abstract][Full Text] [Related]
18. Comparison of survival with somatostatin analog and chemotherapy and prognostic factors for treatment in 165 advanced neuroendocrine tumor patients with Ki-67 20% or less. Özaslan E; Karaca H; Koca S; Sevinç A; Hacioğlu B; Özkan M; Özçelik M; Duran AO; Hacibekiroğlu İ; Yildiz Y; Tanriverdi Ö; Menekşe S; Aksoy A; Bozkurt O; Urvay S; Uysal M; Demir H; Çiltaş A; Dane F Anticancer Drugs; 2017 Feb; 28(2):222-229. PubMed ID: 27768606 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Value of Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914 [TBL] [Abstract][Full Text] [Related]